Bockorny et al. also showed that combined CXCR4 and PD-1 inhibitors promoted an increase in T-cell infiltration and a decrease in MDSCs in pancreatic cancer patients [192]. This evidence concerns the gene CXCR4 and familial pancreatic carcinoma.